

Title: A Phase I/II Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Efficacy Of RO7446603 Administered Alone Or In Combination With Aflibercept Or Faricimab In Patients With Diabetic Macular Edema.

Protocol Number: THAMES GR43828

Condition: Diabetic Macular Edema

Eligible Subjects will be randomly assigned into one of the three study arms:

Arm A: Single intravitreal injection of RO7446603 0.5 mg co-mixed with Faricimab 6 mg at day 1, followed by single intravitreal injection of RO7446603 0.5 mg co-mixed with Faricimab 6 mg week 4 through week 20 at 4 week intervals and from week 28 through week 52 at 8 week intervals.

Arm B: Single intravitreal injection of RO7446603 0.15 mg co-mixed with Faricimab 6 mg at day 1, followed by single intravitreal injection of RO7446603 0.15 mg co-mixed with Faricimab 6 mg week 4 through week 20 at 4 week intervals and from week 28 through week 52 at 8 week intervals.

Arm C: Intravitreal injection of Faricimab 6 mg alone at day 1, followed by Intravitreal injection of Faricimab 6 mg alone week 4 through week 20 at 4 week intervals and from week 28 through week 52 at 8 week intervals

Final Visit for all Arms A, B and C: Week 56

Sponsor: Genentech, Inc.

Royal Oak Site:

Principal Investigator: Jeremy D. Wolfe, M.D.

Coordinators: Natalia Gomez

248-288-9132 ext. 1315

Dawn Gedvilas

248-288-9132 ext. 1334